Case l:14-cv-00914-UNA Document 4 Filed 07/11/14 Page 1 of 1 PagelD #: 125
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`for the District of Delaware
`filed in the U.S. District Court
`on the following
`Sf Patents.
`( • the patent action involves 35 U.S.C. § 292.):
`
`• Trademarks or
`
`DOCKET NO.
`
`DATE FILED
`7/11/2014
`
`PLAINTIFF
`CUBIST PHARMACEUTICALS, INC.
`
`U.S. DISTRICT COURT
`for the District of Delaware
`
`DEFENDANT
`FRESENIUS KABI USA, LLC
`
`PATEN T OR
`TRADEMARK NO.
`6,468,967
`
`DATE OF PATENT
`OR TRADEMARK
`10/22/2002
`
`2 6,852,689
`
`3 8,058,238
`
`4 8,129,342
`
`5
`
`2/8/2005
`
`11/15/2011
`
`3/6/2012
`
`HOLDER OF PATENT OR TRADEMARK
`
`Cubist Pharmaceuticals, Inc.
`
`Cubist Pharmaceuticals, Inc.
`
`Cubist Pharmaceuticals, Inc.
`
`Cubist Pharmaceuticals, Inc.
`
`In the above—entitled case, the following patent(s)/ trademark(s) have been included:
`
`DATE INCLUDED
`
`INCLUDED BY
`
`PA TENT OR
`TRADEMARK NO.
`
`• Amendment
`DA TE OF PATENT
`OR TRADEMARK
`
`• Answer
`
`n Cross Bill • Other Pleading
`HOLDER OF PATENT OR TRADEMARK
`
`2
`
`3
`
`4
`
`5
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`
`DECISION/JUDGEMENT
`
`CLERK
`
`(BY) DEPU TY CLERK
`
`DATE
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`
`1 of 424
`
`FRESENIUS-KABI, Exh. 1003
`
`

`
`Case l:13-cv-06016-NLH-JS Document 4 Filed 10/10/13 Page 1 of 1 PagelD: 126
`
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark
`Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Court for the District of New Jersey on the following:
`Trademarks or X Patents. (
`the patent action involves 35 U.S.C. § 292.)
`
`DOCKET NO.
`DATE FILED
`3:13-e v-06016-M AS-DE/A0/2013
`PLAINTIFF
`CUBIST PHARMACEUTICALS, INC.
`
`U.S. DISTRICT COURT
`TRENTON. NJ
`DEFENDANT
`STRIDES, INC.
`
`PATENT OR
`TRADEMARK NO.
`1 6,468,967
`
`DATE OF PATENT
`OR TRADEMARK
`10/22/2002
`
`2 6,852.68962
`
`3 8,058,238
`
`4 8,129,34262
`
`2/8/2005
`
`11/15/2011
`
`3/6/2012
`
`HOLDER OF PATENT OR TRADEMARK
`
`CUBIST PHARMACEUTICALS, INC
`
`CUBIST PHARMACEUTICALS, INC
`
`CUBIST PHARMACEUTICALS, INC
`
`CUBIST PHARMACEUTICALS, INC
`
`In the above—entitled case, the following patent(s)/ trademarkCs) have been included:
`DATE INCLUDED
`INCLUDED BY
`
`Amendment
`
`Answer
`
`Cross Bill
`
`Other Pleading
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`1
`
`3
`
`4
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`DECISION/JUDGEMENT
`
`CLERK
`William T. Walsh
`
`(BY) DEPUTY CLERK
`s/ KIM STILLMAN
`
`DATE
`10/10/2013
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`C'opj 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`
`2 of 424
`
`

`
`Case l:13-cv-01679-UNA Document 4 Filed 10/09/13 Page 1 of 1 PagelD #: 125
`
`AO 120 fRev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`REPORT ON THE
`FILING OR DETERMINATION OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. §1116 you arc hereby advised that a court action has been
`for the District of Delaware
`filed in the U.S. District Court
`on the following
`( • the patent action involves 33 U.S.C. § 292.):
`• Trademarks or
`Bf Patents.
`
`DOCKET NO.
`
`DATE KILKD
`10/9/2013
`
`U.S. DISTRICT COURT
`for the District of Delaware
`
`PLAINTIFF
`CUBIST PHARMACEUTICALS, INC.
`
`DEFENDANT
`STRIDES, INC. and AGILA SPECIALTIES PRIVATE
`LIMITED
`
`PATENT OR
`TRADEMARK NO.
`I 6,468,967 81
`
`DATE OF PATENT
`OR TRADEMARK
`10/22/2002
`
`HOLDER OF PATENT OR TRADEMARK
`
`Cubist Pharmaceuticals, Inc.
`
`2/8/2005
`
`Cubist Pharmaceuticals, Inc.
`
`11/15/2011
`
`Cubist Pharmaceuticals, Inc.
`
`3/6/2012
`
`Cubist Pharmaceuticals, Inc.
`
`In the above—entitled case, the following patently trademarlc(s) have been included:
`INCLUDED BY
`
`• Amendment • Answer
`DATE OF PATENT
`OR TRADEMARK
`
`• Cross Bill • Other Pleading
`
`HOLDER OF PATENT OR TRADEMARK
`
`2 6,852,689 62
`
`3 8,058,238 82
`
`4 8,129,342 82
`
`5
`
`DATE INCLUDED
`
`PATENT OR
`TRADEMARK NO.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`DECISIONUUDGEMENT
`
`CLERK
`
`(BY) DEPUTY CLERK
`
`DATE
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon ttrmination of action, mail this copy to Director
`Copy 2—Upon filing document adding p«tent(s), mail this copy to Director Copy 4—Case file eopy
`
`
`3 of 424
`
`

`
`Case 3:13-cv-06016-MAS-DEA Document 4 Filed 10/10/13 Page 1 of 1 PagelD: 126
`
`AO 120 (Rev. 08/10)
`
`TO:
`
`Mail Stop 8
`Director of the U.S. Patent and Trademark
`Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`FILING ORD^ERMlNA/nON OF AN
`ACTION REGARDING A PATENT OR
`TRADEMARK
`
`In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been
`filed in the U.S. District Court for the District of New Jersey on the following:
`the patent action involves 35 U.S.C. § 292.)
`Trademarks or X Patents. (
`
`DOCKET NO.
`DATE FILED
`3:13-cv-06016-MAS-t])E/A0/2013
`PLAINTIFF
`CUBIST PHARMACEUTICALS, INC.
`
`U.S. DISTRICT COURT
`TRENTON. NJ
`DEFENDANT
`STRIDES, INC.
`
`PATENT OR
`TRADEMARK NO
`1 6,468,967
`
`DATE OF PATENT
`OR TRADEMARK
`10/22/2002
`
`2 6,852,689B2
`
`3 8,058,238
`
`4 8,129,342B2
`
`5
`
`2/8/2005
`
`11/15/2011
`
`3/6/2012
`
`HOLDER OF PATENT OR TRADEMARK
`
`CUBIST PHARMACEUTICALS, INC
`
`CUBIST PHARMACEUTICALS, INC
`
`CUBIST PHARMACEUTICALS, INC
`
`CUBIST PHARMACEUTICALS, INC
`
`In the above—entitled case, the following patentfsV trademarkfs) have been included:
`INCLUDED BY
`DATE INCLUDED
`
`Amendment
`
`Answer
`
`Cross Bill
`
`Other Pleading
`
`DATE OF PATENT
`OR TRADEMARK
`
`HOLDER OF PATENT OR TRADEMARK
`
`PATENT OR
`TRADEMARK NO
`1
`2
`3
`
`4
`
`5
`
`In the above—entitled case, the following decision has been rendered or judgement issued:
`DECISION/JUDGEMENT
`
`CLERK
`William T. Walsh
`
`(BY) DEPUTY CLERK
`s/ KIM STILLMAN
`
`DATE
`10/10/2013
`
`Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
`Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy
`
`
`4 of 424
`
`

`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO.
`APPLICATION NO.
`DATED
`INVENTOR(S)
`
`8,058,238 B2
`11/739180
`November 15, 2011
`Thomas Kelleher et al.
`
`Page 1 of 1
`
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:
`
`IN THE CLAIMS:
`
`In Column 45, line 38, Claim 139, replace "claim 48" with ~ claim 49 —.
`
`In Column 47, lines 57 and 58, Claim 176, replace "greater than or 93%" with
`93% ~.
`
`greater than or about
`
`Signed and Sealed this
`Twenty-fourth Day of January, 2012
`
`David J. Kappos
`Director of the United States Patent and Trademark Office
`
`
`5 of 424
`
`

`
`m THE UNIFED STATES PATENT AND TRADEMARK. OFFICE
`
`Confirmation No.:
`
`8837
`
`Appl. No.
`
`: 11/739,180
`
`Patent No.
`
`: 8,058,238 B2
`
`Applicant
`
`: Thomas Kelieher et a!.
`
`filed
`
`Issued
`
`: April 24, 2007
`
`: November 15, 2011
`
`TC/A.U.
`
`: 1656
`
`Examiner
`
`: Chih Min Kam
`
`Docket No,
`
`: €062-02/03 US
`
`Customer No. : 34.103
`
`... q 1.322
`
`Applicants hereby request that a Certificate of Correction be issued in the patent identified
`above. The errors to be corrected are of a minor, typographical nature and are described in detail
`on the enclosed PTQ/SB/44 form..
`The errors occurred through the fault of the office; therefore, no fee is believed due at this
`time. Please charge deposit account no. 50-1986 if any fees are believed due at this time.
`
`Respectful iy so bmitted,
`
`/Nicholas M. Boivin/
`Nicholas M. Boivin, Reg. No. 45,650
`Attorney for Applicants
`
`Dated: December .28, 2011
`
`Cubist Pharmaceuticals, Inc.
`65 Hayden Avenue
`Lexington, Massachusetts 02421
`Tel; (781) 860-8660
`Fax:(781) 860-1407
`
`
`6 of 424
`
`

`
`PTO/SB/44 (ua-CVj
`Approved for use fhrouch eae!/2013. Omi O&St-fKiaa
`U.S. Patent and TraOemaf* Office; U.S. DEPARTMENT OF COUfflWiRCE
`Under the PjsperAXMt, Re<juc.i!<Jn Act of 1995. no oeisons are requires to respontitoa coaectsQr! of infomiafion uatess ii displays a vaiici OMB controf nurntejf
`{Also Fwm PTO-1050}
`aMMWWWMMPMnOTOTmMOMeOMMMI
`
`CERTIFICATE OF CORRECTION
`
`PATENT NO.
`: 8,058,238 82
`APPLICATION NO.: 11/739.180
`ISSUE DATE
`: November 15, 2011
`
`INVENTOR'S)
`
`: Thomas Ksfteher el a(.
`
`Page
`
`1
`
`of 1
`
`it is certified that an error appears' or errors appear in the above-identified patent and that said tetters Pateiit
`is hereby corrected as shown below:
`
`In Column 45, Sine 38, replace "claim 48" with — claim 49
`
`in Column 47, fines 57 and 58, repiace "greater than or 33%" with — greater than or about 93%
`
`MAii-iNG ADDRESS OF SENDER (Please do not use customer number below):
`Nicholas Boivin, Cubist Pharmaceuticsis, inc.
`65 Hay den Avenue
`Lexington, MA 02421
`This colfesion of inferniattofi is rsquirea by 37 CFf? 1.322; 1:32.3, and: 1.324, The iriformatrofi is required to Otilain or.retain a benafrt by iheipubiiqv/fjiGfi is to fite-
`land fey. the USPTO to processi an application, Oonficleniiality $ gcwemsd by 35 US.C. 122 mi W GFR ".U. 'this.collection is esBmrtadiito'^lw'.iJW-.tO;
`Gornpfete. including gatheilng. preparing, anci su&mitting: the compistsd application form to the .USPTO. Time wii! vary cependirtg upon the indivsdual case..Any
`fiommants on tt»8 amount of time yau require to complete this form snd/pr suggestisns for reducing this burden, should be. sent to ins Chief in'orfrisiio.fi Officer,
`U.S. Patent and Trademaifc Office: U.S. Departmsnt of Commsrce. P.O. Box. 1460. Alexarxiria: VA 22313.J!'15Q, DO NOT SEND FEES OR
`FORMS TO THIS ADDRESS. SENO TO: Attention Certificate of Corrections Branch, Comniissioner for Patents, P.O. Box 1450, Atexandria,
`VA 22313-1450.
`
`If yau need assistance- in compieiing the form, cai! 1-8Q0-P7Q~9199 and select option 2..
`
`
`7 of 424
`
`

`
`Electronic Acknowledgement Receipt
`
`EFSID:
`
`Application Number:
`
`11717005
`
`11739180
`
`International Application Number:
`
`Confirmation Number:
`
`8837
`
`Title of Invention:
`
`HIGH PURITY LIPOPEPTIDES
`
`First Named Inventor/Applicant Name:
`
`Thomas Kelleher
`
`Customer Number:
`
`34103
`
`Filer:
`
`Nicholas M.C. Boivin
`
`Filer Authorized By:
`
`Attorney Docket Number:
`
`C062-02/03 US
`
`Receipt Date:
`
`Filing Date:
`
`Time Stamp:
`
`28-DEC-2011
`
`24-APR-2007
`
`14:21:51
`
`Application Type:
`
`Utility under 35 USC 111(a)
`
`Payment information:
`
`Submitted with Payment
`
`no
`
`File Listing:
`
`Document
`Number
`
`Document Description
`
`File Name
`
`File Size( Bytes)/
`Message Digest
`
`Multi
`Part /.zip
`
`Pages
`(ifappl.)
`
`1
`
`Request for Certificate of Correction
`
`C062_02_03_US_20111228_Ce
`rt_of_Cor.pdf
`
`658909
`
`8c4bfebf445df90149f66e4a65fb01 bdSfl 85
`909
`
`no
`
`2
`
`Warnings:
`
`Information:
`
`
`8 of 424
`
`

`
`Total Files Size (in bytes):
`
`658909
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`
`9 of 424
`
`

`
`^ UNITED STATES PATENT AND TRADEMARK OFFICE
`1
`
`it
`1
`
`•AT OF CO
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Bo DX 1450
`dria, Virginia 22313-1450
`Alexan
`to.gov www.usp
`
`
`APPLICATION NO.
`
`11/739,180
`
`ISSUE DATE
`
`11/15/2011
`
`PATENT NO.
`
`8058238
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`C062-02/03 US
`
`8837
`
`34103
`7590
`10/26/2011
`Intellectual Property Department
`Cubist Pharmaceuticals, Inc.
`65 Hayden Avenue
`Lexington, MA 02421
`
`The projected patent number and issue date are specified above.
`
`ISSUE NOTIFICATION
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include
`an indication of the adjustment on the front page.
`
`If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that
`determines Patent Term Adjustment is the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEB site (http://pair.uspto.gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management
`(ODM) at (571)-272-4200.
`
`APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):
`
`Thomas Kelleher, Weston, MA;
`Jan-Ji Lai, Westborough, MA;
`Joseph P. DeCourcey, Charlestown, MA;
`Paul Lynch, Arlington, MA;
`Maurizio Zenoni, Milan, ITALY;
`Auro Tagliani, Pavia, ITALY;
`
`IR103 (Rev. 10/09)
`
`
`10 of 424
`
`

`
`mk UNITED STATES FkrENT AND TRADEMARK OFFICE
`
`1
`
`I'l
`
`Bib Data Sheet
`
`SERIAL NUMBER
`11/739,180
`
`FILING OR 371(c)
`DATE
`04/24/2007
`RULE
`
`APPLICANTS
`Thomas Kelleher, Weston, MA;
`Jan-Ji Lai, Westborough, MA;
`Joseph P. DeCourcey, Charlestown, MA;
`Paul Lynch, Arlington, MA;
`Maurizio Zenoni, Milan, ITALY;
`Auro Tagliani, Pavia, ITALY;
`
`UNITED STATES DEPARTMENT OF COMMEKCE
`United States Potent and Trademark Office
`Addrew: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.mpto.gov
`
`CONFIRMATION NO. 8837
`
`CLASS
`514
`
`GROUP ART UNIT
`1656
`
`ATTORNEY
`DOCKET NO.
`C062-02/03 US
`
`*************************
`
`** CONTINUING DATA
`This application is a CON of 10/747,485 12/29/2003 ABN which is a DIV of 09/735,191 11/28/2000 PAT
`6,696,412
`which claims benefit of 60/177,170 01/20/2000
`
`" FOREIGN APPLICATIONS ********************
`
`IF REQUIRED, FOREIGN FILING LICENSE GRANTED
`** 05/08/2007
`Foreign Priority claimed Q yes Q no
`35 USC 119 (a-d) conditions • • • Met after
`yes
`no
`Allowance
`
`STATE OR
`COUNTRY
`MA
`
`SHEETS
`DRAWING
`1 1
`
`TOTAL
`CLAIMS
`53
`
`INDEPENDENT
`CLAIMS
`1
`
`Examiner's Signature
`
`Initials
`
`met
`Verified and
`Acknowledged
`ADDRESS
`34103
`TITLE
`HIGH PURITY LIPOPEPTIDES
`
`FILING FEE
`FEES: Authority has been given in Paper
`RECEIVED No.
`to charge/credit DEPOSIT ACCOUNT
`for following:
`No.
`8591
`
`• All Fees
`
`• 1.16 Fees ( Filing )
`
`• 1.17 Fees ( Processing Ext. of
`time)
`Q 1.18 Fees (Issue )
`Q Other
`• Credit
`
`
`11 of 424
`
`

`
`TANTl
`
`|l
`
`WJ
`
`UNITED STATES FKTENT AND TRADEMARK OFFICE
`
`APPLICATION NUMBER
`11/739,180
`
`I
`
`FILING OR 371 (C) DATE
`04/24/2007
`
`I
`
`34103
`Intellectual Property Department
`Cubist Pharmaceuticals, Inc.
`65 Hayden Avenue
`Lexington, MA 02421
`
`UNITED STATES DEPARTMENT OE COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Yiigmia
`www.uspto.gov
`FIRST NAMED APPLICANT
`Thomas Kelleher
`
`I
`ATTY. DOCKET NO./TITLE
`C062-02/03 US
`CONFIRMATION NO. 8837
`POA ACCEPTANCE LETTER
`
`22313-1450
`
`;000000050087820'
`
`Date Mailed: 09/29/2011
`
`NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY
`This is in response to the Power of Attorney filed 09/08/2011.
`
`The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the
`above address as provided by 37 CFR 1.33.
`
`/cbowen/
`
`Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101
`
`page 1 of 1
`
`
`12 of 424
`
`

`
`fl
`5 K
`
`ST
`
`f-V
`
`rf
`
`J
`££
`
`lllll
`P Hill «I ysi "
`s: f S- S A ^ 1 1 <rZdJ
`i isssi a! iiis
`< ;H
`
`S s
`
`!•*<
`
`•w-
`ij
`
`sei ^
`H* ^
`~ 3
`£ :i a.
`JZ
`£
`
`&
`
`a
`ts w
`=3
`
`w
`
`I
`*£5
`5
`ii
`
`c
`
`"ig?
`3 fll
`
`rl;
`'-/Z
`',< %••
`•7:
`'"•* ' v
`•P-
`sr?
`si!
`Ill 5
`Pi «
`•*2£
`IP I
`•n"
`i?
`I p £
`- . v
`«v. S
`£
`aim
`5 5 if!
`I^p I
`t ii S I £ 111!
`
`|
`
`t-r
`
`
`
`-
`
`S'T S S
`
`i :=; i
`£. ii
`^ --
`^:
`? Il = I
`£ III
`. | | | §
`S J 7 &' S';
`3 a I S - g
`)••«- ••rS '••«.
`^ :•". 'C! ^
`
`---•'
`
`.^".
`
`"-. i<C,
`
`1
`§ S
`
`If!
`.c: v..
`III
`311
`ill isi
`cV,^
`.^P IP
`•fi.g
`Jll jIL iHi!
`js-gi IfeS sS^ig^-s
`fit ^ii Y*m\
`J-Sf is 55 s
`-It fin li^
`Islf ^1|?=
`:8S"P
`::4 1I« lili ,fef ^
`'f gf-r
`,=• :: r .:;:>
`isliH -Si^v
`"
`r'S-S
`i'^n
`
`: ti .-5/" ^ n
`
`^
`
`•-j ^2
`
`.^«5
`
`1M
`111 I 1 3
`ill li
`ill
`
`fflSfe
`
`.sxSw-f
`
`?
`
`X
`
`J,
`
`s
`P, :
`
`^ 4 e R
`•< •:•
`JA i
`@1
`U;
`
`3
`•$ i O i
`
`-^-i
`
`•A
`}<
`
`r- 5 -
`
`i.
`i
`
`s
`
`w
`
`s:
`
`-f;.
`
`s ^•
`•'.i ^
`
`>•.,
`JC'
`
`.! 5 n I
`y l
`g i s
`i $
`•• i
`•5 !
`::; S
`- i £ j
`
`Ji. i
`
`&
`
`I!S
`'••*•
`^ S
`
`.£ •c.
`
`,,
`
`fi s
`
`••: V'
`
`15
`
`»
`
`g =
`M
`I
`1 p
`S ^
`r s s
`K C
`r ^ £5 1
`.:i
`r,
`s.
`- -
`::;
`'s "
`i1 Hi
`li ML
`,• f"
`i t ~9
`I %ll! E !f is
`fliftil fill®
`:3||| !5 •S.c gjj
`, 4 i ii mi g H11
`! - i!&Sri lilll
`
`I
`a
`
`£
`
`u
`
`S:i
`
`3
`
`I
`
`I ! gl
`•„
`-•?
`s15
`r II '—
`" ^
`is
`
`11
`<S-
`
`•:jj "
`
`fe n ts
`^ ?-
`S
`- SE
`
`^ |5 g
`K -=!-
`
`Mi
`i i-rlVi
`; It:!?
`i m m
`I li i
`1 III I
`--Sufi
`1W? i
`. i m i
`i is ifa I
`# iii^ «
`^
`§
`1 l-Pfg I
`a i JiliS ;
`I
`a s ||.:ra
`fill? I
`= -'3oi
`«
`. Ill !
`I iJs-ft 1
`HS I
`I IPlg I
`1'?
`- n
`J.
`3E?1| 1
`i'lfS f
`i' 11 a!
`i!?lvll-g! 3! S
`«i"R K\|! 5811 1
`Jr
`"? I' S'5
`^ \
`v.
`I ?-:£!
`"
`t E ll ^ §1
`15 §1 v
`iiiisi 5
`" ' "•
`i;±! g«|£?L <
`4a! litirti
`S ~i 3 "
`•S 2 1=3
`3 % • £ a
`V
`^ fs "2 St-
`i 1 III®!
`tl li
`•» i «n§s
`, .. 5 c I I:1«
`j- s u m i
`|
`M i l « t M I
`1 1 1 1
`I lllllll
`^ <
`" laiir
`
`I:"'
`
`•-;
`
`Si s
`^ t
`I I
`s I :'0 ^,
`S
`c I
`S 1
`y. ^
`^ -
`I i
`L:; ^
`•y —'
`
`ll S ij
`S!^
`~ M
`K 2
`III
`4 :=:-J: w:ii
`
`' »D r~;
`
`ii
`
`$1 $\
`
`Cpj=30
`
`:
`
`• £ • % # % 2'J; 3
`
`•fl
`
`;s;
`5=
`
`'€
`X;;
`
`s
`
`'•j^:
`
`.y-;
`
`M §
`|
`I
`"i
`I
`
`L/",
`
`•r-'j
`
`•S
`
`C;
`
`'>
`
`;
`
`•:;; t
`
`•5
`
`'£
`I
`
`=<
`
`:ju
`
`"•••£ :
`o
`S o
`i;" S:&
`- I | a
`is
`1 I
`:I:S
`y |
`li
`^ J
`I'J
`1 I
`•5- J
`I I
`•S i "4 "W:.
`£
`§ 1
`I I III
`m f 311
`1 1 £ P
`s 1 'Sg
`f
`*3
`f -•<
`^ "7
`£
`#
`a u m
`i Si isa
`s
`U
`"* -5 B ^ £•
`1 = £ ^ - 5 !
`I zno§
`S. 5
`i5
`1 ::;
`
`l
`
`l
`
`
`
`• r l V i n I P | a I j i s
`i% l! s si: E | s ? < p
`®
`M 811* Sllllsl i ii
`< i II ii is Si
`5?
`" $ Ss 4^.2 * o~ OB M , I
`,1 S g 33 m ^
`I
`a li ill ! si •'
`!
`j
`
`--'2 '5^.2 2j ^ S « Jj
`
`<3*- :-'
`
`-
`
`<••..
`
`-?
`
`§ ': .: S Eg
`
`s |
`
`3
`
`S
`"
`&
`
`^
`S
`\ l-;: §
`
`^ " r •
`
`f
`3 ^
`
`^
`
`I
`i-
`
`..
`
`
`13 of 424
`
`

`
`Electronic Patent Application Fee Transmittal
`
`Application Number:
`
`Filing Date:
`
`11739180
`
`24-Apr-2007
`
`Title of Invention:
`
`HIGH PURITY LIPOPEPTIDES
`
`First Named Inventor/Applicant Name:
`
`Thomas Kelleher
`
`Filer:
`
`Attorney Docket Number:
`
`Filed as Large Entity
`
`Utility under 35 USC 111 (a) Filing Fees
`
`Nicholas M.C. Boivin
`
`C062-02/03 US
`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USD($)
`
`Basic Filing:
`
`Pages:
`
`Claims:
`
`Miscellaneous-Filing:
`
`Petition:
`
`Patent-Appeals-and-lnterference:
`
`Post-Allowance-and-Post-lssuance:
`
`Utility Appl issue fee
`
`Publ. Fee- early, voluntary, or normal
`
`1501
`
`1504
`
`1
`
`1
`
`1740
`
`300
`
`1740
`
`300
`
`
`14 of 424
`
`

`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USD($)
`
`Extension-of-Time:
`
`Miscellaneous:
`
`Total in USD ($)
`
`2040
`
`
`15 of 424
`
`

`
`Electronic Acknowledgement Receipt
`
`EFSID:
`
`Application Number:
`
`10975756
`
`11739180
`
`International Application Number:
`
`Confirmation Number:
`
`8837
`
`Title of Invention:
`
`HIGH PURITY LIPOPEPTIDES
`
`First Named Inventor/Applicant Name:
`
`Thomas Kelleher
`
`Customer Number:
`
`34103
`
`Filer:
`
`Nicholas M.C. Boivin
`
`Filer Authorized By:
`
`Attorney Docket Number:
`
`C062-02/03 US
`
`Receipt Date:
`
`Filing Date:
`
`Time Stamp:
`
`26-SEP-2011
`
`24-APR-2007
`
`16:41:04
`
`Application Type:
`
`Utility under 35 USC 111(a)
`
`Payment information:
`
`Submitted with Payment
`
`Payment Type
`
`Payment was successfully received in RAM
`
`RAM confirmation Number
`
`Deposit Account
`
`Authorized User
`
`yes
`
`Deposit Account
`
`$2040
`
`3032
`
`501986
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)
`
`
`16 of 424
`
`

`
`File Listing:
`
`Document
`Number
`
`Document Description
`
`File Name
`
`File Size( Bytes)/
`Message Digest
`
`Multi
`Part /.zip
`
`Pages
`(ifappl.)
`
`1
`
`Issue Fee Payment (PTO-85B)
`
`C062_02_03_US_20110926_lss
`ue_Fee_Payment.pdf
`
`793331
`
`9f96613824221 fde88ff9ff95de976d778442
`620
`
`no
`
`1
`
`Warnings:
`
`Information:
`
`2
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`no
`
`2
`
`32100
`
`02ec42818e2457b177166fa36aec92a9e26
`7f450
`
`Warnings:
`
`Information:
`
`Total Files Size (in bytes):
`
`825431
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`
`17 of 424
`
`

`
`r
`
`pTomm (01:03)
`Approved for use through 11/302011,. OMB CSSI-OOSS
`M.S. PatsnJ awf Trademark.Office: U.S. OEPAR'fWKMr Oi: COiMEfteS
`UncSsrthe PaperA-ork Reaction Act of 1996. no persons are required to respond to 3 eolisciion of ifSformatfeft twiess itdisplsv'S s-vaSd OMS ccmtrof nymber:
`11/739,180
`April 24, 200?
`, Thomas Keileher
`-| High Purity Lipopeptides
`
`! Apsjiicatiors Number
`POWER OF ATTORNEY
`I Filing Date
`OR
`I First Named inventor
`REVOCATION OF POWER OF ATTORNEY
`\ r m
`WITH A NEW POWER OF ATTORNEY
`Art Unit
`AMD
`CHANGE OF CORRESPONDENCE ADDRESS L^nerName
`
`f Chih-Min Ksm
`Attorney Docket Number i 0082-02/03 US
`
`7
`
`| i hereby revoke a!^ previous powers of attorney given in the above-identified application.
`s
`I
`A Power of Attorney is submitted Herewith.
`OR
`i (13
`I hereby sppoini Pracfitioneris) associated with She foltowing Customer
`Number as my/our attorney(a) or agents} to proaecuie the application
`identified above, and to transact afl 6usiness in the United States Patent
`and Trwtemarii Office connected tiwewifli.
`OR
`f hereby appoint Practitioner{s) named below as my/our attomey{s} or 8gent(s) to prosecute 8ie application identified above, arid
`to transact all business in the United States Patent and Trademark Office connected therewith:
`
`34103
`
`PractitiOfW{s) Name
`
`Registration Number
`
`Please recognize or change the correspondence address for the above-identified application to:
`(Xj The address associated with the above-mentioned Customer Number.
`OR
`| | J The address associated with Customer Number:
`Of?
`Firm or
`j
`Individual Namel
`Address
`
`! State
`
`Email
`
`|
`
`i
`
`:
`
`September 8, 2011
`] (781) 860-868G
`
`City
`| Country
`I Tefephone
`I sm the:
`!
`j Applicant/Inventor.
`OS
`Assignee af record of the entire interest. See 37 CFR 3.71.
`Statement under37 CFR 3 73{b} (Form F'TQ/S8/96) submitted h&ew&h or fnad on
`SIGNATURE of Appficant or AssSgnes of Record
`] /Nicholas M. loivin/
`signature
`| Date
`Telephone
`i Nicholas M. Botvin
`Name
`j
`irsteiiectuai Property Counset, Cubist Pharmaceuticals, inc.
`litis and Company
`tSZCg: Signatures of aii the invsniors or assignees of record of tt» entire interest or trieif reprssantafh/eis; are required. Submif muitiple fefms if mors tiiari one I
`i
`signature is required, see below'.
`[Xj "Total of
`1
`a benefit i>y tht> public which is to file (aad yy tne
`by 37 CFR 1,3 V 1.32 8^0 1.33. The jnfOJWStitin is r^quir^cl to 0^3irt or
`This coiieclior-i of infyrrnsftiw is
`USPTO to process) ^ appiication. CorsfkjWftialfTyis governed hy 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This epltecta is estimst&d to take 3 mwiutes to complete,
`including gathftring, pfepafiriQ. and siibmiUing the completed appltcaiion form to the USPTO Time will vary depending upon the indsvkiuaJ case. Any comments on
`the amaurii of Isme you require to cornptete Uvs form and'or SLs^g&siiorss lor reriucfrsg th® burden, should be sent to ihs Chief Infonnation Office?. U S. Patent snd
`Trademark Office, U.S. Department of Commeros. P.O. Box 1A30, Aiexandoa, VA 23313-1460. DO MOT SEND FEES OR COMPLETED FORMS T0:THIS•
`ADDRHSS SEND TO: Comn^issioner for Patents, P.O. Bo* 1450, Aiaxandria. VA 22313-1450.
`If you need assistance m campleting the form, call 1-SOO-PTO-8199 and select option 2.
`
`§
`
`forms are submitted.
`
`
`18 of 424
`
`

`
`r-rc/sa'se •er.c;?:
`AppioveiS tor use ihrouah OWI/ZOJ? OMfS:'j861re®S1:
`U.S, Paierst and TtaetSmwk OiiiCS; UiS, DaPARTMKNrCi' GO^MBRef;
`Under tlie Paperwork Reductsm Ac* of 1995. no persons are reeajlPeS to respond to a crilfecKau'otf infonsua^oh wnlessit cfisplsys a vsrf«3 OMB
`nutfibif..
`III
`•
`b
`ma—— •••••imwwwwj—
`I I L L L LiL'Lt'L'WiM-M-'—'-H
`j j J J ; ; "
`111 in >.1.1.1 • 11 •
`lili' H'll PIM—<W|I < | | il 11 ill . y L
`11 ••»••••
`j
`L
`
`I
`
`STATEMENT UNDER 37 CFR 3.73(bi
`
`Appficant/P'aieni Owner: Ciibist Pharmaceuticals, inc.
`Application No./Patent N».: 1.1/739,180
`1 "ntted:
`
`Fiied/issoe Date: April 24, 2007
`
`Cubist Phafmaceuticais, !Nc.
`(fslsnie
`
`states that it :s:
`
`.8 CorporatiGn
`(Type cs Asaaiiee. e (j., eorpOfaticn. oafifiership, i<rw&rs;!y. gc»«ffifnera aaerv^y. 'ifci
`
`X:
`
`• he assignee of the entire right, titie, and interest in;
`
`2.
`
`j
`
`an assignee of iess than the entire right, title, and Interest in
`(The extent (by percentage} of its awnerstvip interest is
`
`%?: or
`
`the assignee of an undivided interest in the entirety of fa cornpiete assignment frorrs ohe of the joint inveniors was:made)
`]
`3.
`I
`the patent application/patent identified above, by virtue of either
`
`OR
`i B
`
`!X!
`
`An assignment from the inventors) of the patent applicsiion/patent itientifiec! above. The assignmerjt was recoiled in
`the United States Patent and Trsdemark Office at Reel
`, Franie
`, or for which a
`copy therefore is-attached
`
`A chain of title frooi the inventors), of the patent application/patent identified above, to the current assignee as foltows
`TQ: Perseptive Biosystems, !nc
`i. From,:
`inventor Paul D. Lynch
`
`The dQCumenf was recorded in the United States Patent anti Trsdenwk Office at
`Frame 0280
`Reel 0:24070
`or for which a copy theragf is sttaahed.
`
`2. From: Perseptive Biosystems, Inc.
`
`To: Cubist Pharmacsuticals, the.
`
`The document was recorded in She United States Patent and Trademark Office at
`Frame 551J
`Reel 019202
`or for which a copy {hereof is attached.
`
`3. From
`
`Inventors
`
`To- Cubist Pharmaceutieais, Inc.
`
`The documehi was recorded in the United States Patent and Trademark Office at
`0897
`Kee; ota??!
`or for which a copy thereof is attached.
`. Framed
`
`Additional documents in the Ghain -ot titie are listed on a suppiementaf sheetts).
`
`!
`
`| As required by 37 CFR 3.?3(b)(1 )((},• the doeumentarY evidence of the chatn of titie from the original owner to the assigh^i wias;,:
`or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.
`[NOTE A separate copy (i.e., a true copy of the origjnai assignment documents}} must be submitted to
`accordance with 37 CFR Part 3, to record the assignment In the records of the USPTO. See MPEP 302.08]
`
`The undersigned {whose titie is supplied below) is authorized to act on behaif ofthe assignee:
`/Nicholas M. Boivin/
`
`Signature
`
`09/08/2011
`Date
`
`Nicholas M. Boivin
`Printed: or Typed Name
`This eoHscSwi of information is required by 3? CFR 3.?3(b}. The infowiation is requifsri to ybfain ai retain'a benefit by the
`process; 3t> appScalion. Confirssntiaiity is governed-'tjy 35:'tl,S,C.''i:J2 Wnrf.S? CPR 1.11 arid. 1.14. This coiieriion is
`Sphering, pceparing, and submiuing the ecrnptaied appticstion form to the USPTO- Tinns wiil vary depenfling upof> the indivitluai case.:
`you require to .complete this fcrrt; andtor suggsaiions tor racJuoing ftiiB bijrdeh, should be sent so the Chief irifoifMsiicn Officer. UiSOPsteht^risi.-rradaSa'SsSS^^^S;::::::::::®
`Cepaitmem of Commerce. P.O. Box HSQ. Alexsnana, -VA 'aaSig-i-WSOi'DO.KOT SEND FEES OR COWPLETBD FORMS TO THiS: ADDRESS,
`fur Stents, P.O. Broi 1460, ASexandfia, VA 22313-145Q.
`
`(P Counsei
`Title
`
`if you neeci RSsistanos in camp,'e'ifig the. form, call l~8QO-PTQ-919fj andstiedepiior, 2.
`
`
`19 of 424
`
`

`
`O
`
`£ v..-
`
`sy v •A-, v.- »
`
`•>-'
`
`COMPANY:65 HAYDEN AVENUE^ j
`TO:CUB!ST PHARMACEUT1CALS: | p .
`
`i*Nn
`
`h
`
`I
`
`®P£WcS}
`
`IfNSKR SeefffiTAW W COWM5RC6 FOR fcTKUSttaW. PSOPBBTY ftKC
`DIRECTOR WSHS UNtTea ST* rss P*Tiew MO TrtMiJswat Ofr*c
`
`*501117305^
`
`MARCH 12, 2010
`
`CUBIST P^MyiACSaXICSLS,
`gb HAYDEN AVENUE
`INTELLECTUAL PROPERTY SEFAETMENT
`LEXINGTON, M"i 024 21
`
`INC.
`
`PTAS
`
`UNITED 'STATES 'PATENT AND TmomAKK OFFICE
`NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT
`
`THE ENCLOSED DOCOMENT HAS BEEN RECORDED BY THE ASSIGNMENT DCVXSION QF
`THE U.S. PATENT AND TKA0H4ARK OFFICE. K COMPLETE MICKQFTIM COPY JS
`AVAILABLE AT THE SSSIGj^ENT SEARCH ROQ&5 ON. THE REEL AMD FHAME NCMBER
`REFERENCED BELOK.
`
`PLEASE REVIEW ALL INFORMATION